# Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

> **NCT01941316** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cancer Research and Biostatistics Clinical Trials Consortium** · enrollment: 78 (actual)

## Conditions studied

- Small Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Irinotecan Sensitive Cancers

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01941316
- **Lead sponsor:** Cancer Research and Biostatistics Clinical Trials Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-07-01
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2024-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01941316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01941316, "Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01941316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*